The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human -chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
Bruce L. Daugherty - South Orange NJ Julie A. Demartino - Cranford NJ Salvatore J. Siciliano - East Brunswick NJ Martin S. Springer - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07K 14715 C12N 510 C12N 1512 C12N 1564
US Classification:
530350
Abstract:
The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human. beta. -chemokine receptor and has been designated "CC CKR3". The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
Methods For The Use Of Galectin 3 Binding Protein Detected In The Urine For Monitoring The Severity And Progression Of Lupus Nephritis
- Darmstadt, DE Jaromir VLACH - Redding CT, US Nuruddeen Lewis - Andover MA, US Julie DEMARTINO - Westfield NJ, US Roberto BASSI - San Rafael CA, US Wen-Rong LIE - St. Louis MO, US
International Classification:
G01N 33/564 G01N 33/70
Abstract:
Embodiments of the present invention describe compositions and methods incorporating the measurement of LGALS3BP in the urine of patients diagnosed with lupus nephritis (LN) in order to monitor the severity and progression of said LN.